Astellas’ heritage is deeply rooted in the field of transplantation, where we remain a leader today, and we continue to dedicate resources in immunology. Today, we contribute to the area of transplantation with Prograf®, an immunosuppressant used by patients in approximately 100 countries worldwide to prevent rejection in kidney, liver, or heart transplant.

We plan to expand our contribution in this field with several new drug candidates in the late clinical development stage. These include ASP015K, which is under development for the treatment of rheumatoid arthritis and the next-generation vaccine for allergies. We also are working to develop drugs for causal therapy/cure of immune-related disorders, drugs that seek to completely cure immune-related disorders or substantially relieve their symptoms, as well as next-generation innovative, immunoregulatory drugs.